Clinical Trial Update: CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL [Phase 1]

View source ↗

Summary

Phase 1 trial of CAR-20/19-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• CAR-20/19-T cells

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission | Phase 1 | Status: TERMINATED